Fenwick represented Deepcell, a life science company pioneering AI-powered single cell classification and isolation for basic and translational research, in its $73 million Series B financing round. The investment was led by Koch Disruptive Technologies and joined by new investors including Bridger Healthcare, Horizons Ventures, Casdin Capital and lead investors from previous rounds, Andreessen Horowitz and Bow Capital as well as Jeff Dean, Head of Google Brain, and Matt Mcllwain, Managing Director at Madrona Venture Group.
The new capital will allow Deepcell to continue product development and enable early commercial introduction of a new standard for obtaining biological insights from single cell analysis. More information can be obtained from the company’s announcement.
The Fenwick transaction team was led by Michael Esquivel and Stefano Quintini and included associates Ryan McRobert, Shajee Rizvi and Robina Gallagher.